Actively Recruiting

Phase 2
Age: 18Years - 120Years
All Genders
ID06246357

Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

Led by National Cancer Institute (NCI) · Updated on 2025-12-09

80

Participants Needed

1

Research Sites

17 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying adrenal tumors, which are growths on or near the adrenal glands that can be functional (releasing hormones) or nonfunctional. This study aims to see if a new radioactive tracer called [68Ga]Ga-PentixaFor can help identify functional adrenal tumors in people with hyperaldosteronism or hypercortisolism using PET scans. Knowing the tumor type helps doctors choose the best treatment. This is a Phase II study sponsored by the National Cancer Institute involving adults aged 18 and older who have adrenal tumors and increased hormone levels. Participants will receive an injection of [68Ga]Ga-PentixaFor about one hour before undergoing a PET/CT or PET/MR scan to capture images of their adrenal glands. The tracer dose is approximately 150 MBq, given through a vein. The imaging session lasts between 45 and 90 minutes. Participants will have their heart rate, blood pressure, and breathing monitored before, during, and after the scan. After the imaging, a safety check will happen three days later, which can be done by phone, email, or in person. During the study, participants will be screened and have imaging scans along with evaluations of their ability to perform daily activities. They may remain on study for up to one year for additional sample collection and analysis related to their adrenal condition. The main outcome measured is how well the [68Ga]Ga-PentixaFor imaging matches the clinical diagnosis of functional adrenal tumors. Safety and uptake thresholds of the tracer will also be evaluated throughout the study period.

CONDITIONS

Brief Title

Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

Who Can Participate

Age: 18Years - 120Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Must have one or more adrenal masses on CT and/or MRI with biochemical evidence of excess aldosterone
  • OR have ACTH-independent hypercortisolism, with or without adrenal masses on CT and/or MRI
  • OR have a history of ACTH-dependent hypercortisolism, with or without adrenal enlargement
  • Be co-enrolled in NIH trial 19-DK-0066, 09-C-0242, 18-CH-0031 or a similar study
  • Be aged 18 years or older
  • Have an ECOG performance status of 2 or less
  • Women of child-bearing potential and men must agree to use effective contraception for two weeks before and one week after the scan
  • Breastfeeding must be stopped for one week after the scan
  • Men must agree not to donate sperm for one week after the scan
  • Be able to understand and willing to sign informed consent
Not Eligible

You will not qualify if you...

  • Positive pregnancy test in females of childbearing potential at screening
  • Uncontrolled illness or social situations that limit compliance with study requirements
  • Contraindications to having an MRI or CT scan

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person) for screening and enrollment

Diagnostic Evaluation

Duration - 1 day

Participants undergo [68Ga]Ga-PentixaFor PET/CT or PET/MR imaging to evaluate adrenal gland function related to hyperaldosteronism and hypercortisolism.

1 imaging visit (in-person)

Follow-up

Duration - Up to 1 year

Participants have a safety visit 3 days after imaging and remain on study for up to 1 year for additional sample collection and assessments related to adrenal function and study analyses.

1 safety visit plus additional visits as needed for sample collection and assessments

Trial Site Locations

Total: 1 location

1

National Institutes of Health Clinical Center

Bethesda, Maryland, United States, 20892

Actively Recruiting

Loading map...

Research Team

Y

Yolanda L McKinney, R.N.

M

Maria Liza Lindenberg, M.D.

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Similar Trials

A Block-and-Replace Therapy With Osilodrostat and Concomitan...

Endogenous Cushing Syndrome

Actively Recruiting

1 location

China Adrenal Venous Sampling Investigation: A National Mult...

Hyperaldosteronism

Actively Recruiting

76 locations

CXCR4-Targeted PET Imaging for the Differential Diagnosis of...

Cushing s Syndrome

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here